<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Pure Path Pharmacy]]></title><description><![CDATA[we specialize in providing customized medications to help you achieve your health goals. Our focus is on compounded Semaglutide treatments, designed to support weight loss and diabetes management. Every prescription is crafted in-house to ensure the highest quality and personalized care.]]></description><link>https://www.purepathpharmacy.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Wed, 26 Aug 2026 12:42:29 GMT</lastBuildDate><atom:link href="https://www.purepathpharmacy.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Pure Path Pharmacy Is Now Licensed in Georgia and Washington, D.C.]]></title><description><![CDATA[Pure Path Pharmacy is now licensed as a nonresident pharmacy in Georgia and Washington, D.C. This expansion allows eligible provider teams in both jurisdictions to work with Pure Path for patient-specific sterile compounding services, subject to applicable law, current pharmacy capabilities, prescription requirements, and pharmacy review. For Pure Path, adding new jurisdictions is not simply about expanding a map. It is about creating responsible access to a provider-focused pharmacy...]]></description><link>https://www.purepathpharmacy.com/post/pure-path-pharmacy-is-now-licensed-in-georgia-and-washington-d-c</link><guid isPermaLink="false">6a8e089a28d0cf71ca039948</guid><pubDate>Tue, 25 Aug 2026 21:41:13 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/cf893d_ad30deef09e14471a7846df087ca3a90~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Reese Phillips II</dc:creator></item><item><title><![CDATA[What Providers Should Expect From a 503A Sterile Compounding Pharmacy?]]></title><description><![CDATA[Working with a 503A sterile compounding pharmacy should involve more than sending an order and waiting for a package. Provider teams should expect patient-specific prescription review, clear communication, appropriate questions, state-specific service considerations, and coordination among pharmacy professionals. These steps help the pharmacy evaluate each prescription and support an orderly process from receipt through dispensing. What is a 503A sterile compounding pharmacy? A 503A sterile...]]></description><link>https://www.purepathpharmacy.com/post/what-providers-should-expect-from-a-503a-sterile-compounding-pharmacy</link><guid isPermaLink="false">6a85bb096413fe3757859f11</guid><pubDate>Wed, 19 Aug 2026 14:34:11 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/cf893d_388293c0869e48dbbbc7e8570477e8dc~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Reese Phillips II</dc:creator></item><item><title><![CDATA[A New Approach to the Compounded Injectable Experience: Pure Path Pharmacy and the UniPen Platform]]></title><description><![CDATA[The experience surrounding compounded injectable medications is changing. For healthcare providers, the conversation is no longer limited to the medication itself. Packaging, administration, patient education, pharmacy workflow, and the overall experience can all play a role in how practices evaluate pharmacy solutions. At Pure Path Sterile Compounding Pharmacy, we believe those details matter. That is one reason we are excited about the potential of innovative injection-device platforms such...]]></description><link>https://www.purepathpharmacy.com/post/a-new-approach-to-the-compounded-injectable-experience-pure-path-pharmacy-and-the-unipen-platform</link><guid isPermaLink="false">6a7de13ad249a633b9d66d88</guid><pubDate>Thu, 13 Aug 2026 15:34:24 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/cf893d_7f98966abfaa4db88fbfcf0b8067f0c4~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Reese Phillips II</dc:creator></item></channel></rss>